News · Reforgene Medicine

2026.10.26

Reforgene’s Two Gene-Editing Therapies Selected for the 33rd ESGCT Annual Congress; RM001 to Be Featured in an Oral Presentation

Reforgene Medicine today announced that its investigational gene-editing therapies, RM001 and RM004, have been selected for presentation at the 33rd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), taking place October 27–30, 2026, in Hamburg, Germany.

Newsroom

Reforgene’s Two Gene-Editing Therapies Selected for the 33rd ESGCT Annual Congress; RM001 to Be Featured in an Oral Presentation

Latest Updates

Reforgene Medicine Announces Major Progress in Pivotal Phase 2 Trial of RM001 for β-Thalassemia

Reforgene's TitanCas12i™ Gene-Editing Patents Granted in China and the United States

Reforgene named among China's Top 100 Innovative Pharmaceutical Companies 2026

Reforgene named a Future Healthcare Top 100 company for the fourth consecutive year

TIF and the Angel Mama Foundation visit Reforgene to advance global access for thalassemia gene medicine

Reforgene approved as a postdoctoral research workstation sub-station

Reforgene listed among China's 2025 biopharma frontrunners

Reforgene named a 2024 Top 50 most influential healthcare company

Reforgene named a 2025 Future Healthcare Top 100 company for the third consecutive year

World Thalassemia Day: Reforgene contributes China's innovative medicine solutions toward a thalassemia-free world

Guangzhou Industrial Investment Group visits Reforgene

Reforgene raises hundreds of millions of RMB in a new financing round to advance gene editing drug development

Reforgene named a Guangzhou Future Unicorn for the third consecutive year

Reforgene ranks in Guangzhou's 2024 Top 10 science and technology leaders

Reforgene named a potential unicorn enterprise in China for the second consecutive year

Reforgene gene editing drug program approved under the National Key R&D Program disruptive technology innovation special project

China approves IND for Reforgene's first-in-class Usher syndrome gene editing medicine

U.S. FDA approves IND for Reforgene's first-in-class Usher syndrome gene editing medicine

From lab to global stage: Reforgene advances international patent portfolio for its novel CasRm gene editing system

Reshaping destiny: China's first adult thalassemia gene therapy patient heads to university

World's first cure of an alpha-thalassemia patient with a gene editing drug: another Reforgene breakthrough

Reforgene named a 2024 Future Healthcare Top 100 company for the second consecutive year

Reforgene completes dosing of all patients in the Phase I trial of its thalassemia gene editing drug RM001

Reforgene again named a Guangzhou Future Unicorn enterprise

Reforgene named a 2022 potential unicorn enterprise of Huangpu District and Guangzhou Development District

Reforgene reports Phase I progress for its thalassemia gene editing drug RM001

Kick-off meeting held for Reforgene's Guangdong Provincial Key R&D Program project

Reforgene named a potential unicorn enterprise in China

Reforgene named a 2023 Future Healthcare Top 100 company

Reforgene completes hundreds of millions of RMB in Pre-B financing to advance the world's first novel-target beta-thalassemia gene editing drug trial

Reforgene named a 2022 Guangzhou Future Unicorn enterprise

Clinical progress of Reforgene's thalassemia gene editing drug RM001 to be presented at ASH 2022

NMPA approves IND for Reforgene's beta-thalassemia gene editing medicine

CDE accepts IND application for Reforgene's novel-target thalassemia gene editing medicine

Reforgene passes intellectual property management system certification

Reforgene ranks in the 2021 healthcare Top 15 Best Emerging Enterprise award

Reforgene presents novel-target gene editing thalassemia clinical results at EHA 2022

Reforgene wins Best Biopharmaceutical Company of the Year in the healthcare investment awards

Reforgene named a Top 10 cell and gene therapy company in the 2021 biopharma value rankings

Reforgene wins Emerging Biotech with the Most Investment Potential of the Year

Reforgene presents at BIO-PHARM 2021 on the development and challenges of innovative gene editing medicines

Reforgene named a Top 10 China medical innovation company 2021

Reforgene named a 2021 Top 50 most innovative Chinese biopharma company

Reforgene completes A+ round financing and enters a new stage of pipeline development

Reforgene named a GHRC 2020 Best Employer brand

Reforgene completes nearly 100 million RMB Series A financing to accelerate gene editing therapy development

Reforgene recognized as a technology-based SME

Reforgene presents at the 4th China Gene Therapy Industry Development and Product Quality Control Forum

Reforgene attends the 2019 International Innovative Biotechnology Symposium